Editorial response: Choosing amphotericin B formulations - Between a rock and a hard place

Clinical Infectious Diseases

Volumn 31, Issue 5, 2000, Pages 1164-1165

  Bennett, J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX;

CLINICAL TRIAL; DRUG COST; DRUG FORMULATION; EDITORIAL; FEBRILE NEUTROPENIA; HUMAN; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; COLLOIDS; DRUG CARRIERS; HUMANS; LIPOSOMES;

EID: 0034456020     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/317443     Document Type: Editorial

References (3)

1. A randomized, double blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
2. Randomized, double blind comparison of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
3. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia